Neopterin and Soluble Urokinase Type Plasminogen Activator Receptor as Biomarkers in Dogs with Systemic Inflammatory Response Syndrome
Abstract
The systemic inflammatory response syndrome (SIRS) is a common cause of mortality in dogs. This study aims to investigate the diagnostic value of markers C-reactive protein (CRP), soluble urokinase-type plasminogen activator receptor (suPAR) and neopterin in dogs with SIRS. The materials of the study consist of 30 dogs with SIRS and 15 healthy dogs that show no clinical symptom, 45 dogs in total. CRP, suPAR and neopterin levels of the serum samples were determined by ELISA using commercial kits. In the study, it was found that CRP, suPAR and neopterin levels of dogs with SIRS were significantly higher (P < 0.001, P < 0.01 and P < 0.01, respectively) than those in the healthy group. The cut-off values for the healthy dogs and dogs with SIRS for CRP, suPAR and neopterin were determined to be 11.20 mg/L, 223.68 ng/L and 3.23 nmol/mL, respectively. At these cut-off values, sensitivity levels were determined as high (92.90%) for CRP, moderate (63.30%) for neopterin, and low (53.30%) for suPAR, and high specificities (93.30%) were determined for all. In conclusion, it was determined that CRP showed the best performance for the detection of systemic inflammatory response in dogs and neopterin and suPAR could be used as an alternative to CRP. It was also argued that further studies were necessary in order to determine diagnosis and prognosis of diseases.
Article Details
- How to Cite
-
BASBUG, O., AYDOGDU, U., & AGAOGLU, Z. T. (2020). Neopterin and Soluble Urokinase Type Plasminogen Activator Receptor as Biomarkers in Dogs with Systemic Inflammatory Response Syndrome. Journal of the Hellenic Veterinary Medical Society, 71(1), 1945–1952. https://doi.org/10.12681/jhvms.22936
- Issue
- Vol. 71 No. 1 (2020)
- Section
- Research Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.